|Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade|
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
|Neoadjuvant PD-1 blockade in resectable lung cancer|
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
|Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancerdynamics of neoantigen landscape during immunotherapy|
V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ...
Cancer discovery 7 (3), 264-276, 2017
|Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)|
TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ...
Annals of Oncology 29 (8), 1853-1860, 2018
|Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer|
V Anagnostou, PM Forde, JR White, N Niknafs, C Hruban, J Naidoo, ...
Cancer research 79 (6), 1214-1225, 2019
|Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers|
JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ...
Nature 596 (7870), 126-132, 2021
|Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer|
V Anagnostou, N Niknafs, K Marrone, DC Bruhm, JR White, J Naidoo, ...
Nature cancer 1 (1), 99-111, 2020
|Redundant innate and adaptive sources of IL17 production drive colon TumorigenesisIL17 and microbial-induced colon cancer|
F Housseau, S Wu, EC Wick, H Fan, X Wu, NJ Llosa, KN Smith, A Tam, ...
Cancer research 76 (8), 2115-2124, 2016
|The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor ImmunityMANAFEST Assay for Detecting …|
L Danilova, V Anagnostou, JX Caushi, JW Sidhom, H Guo, HY Chan, ...
Cancer immunology research 6 (8), 888-899, 2018
|Metabolic programs define dysfunctional immune responses in severe COVID-19 patients|
EA Thompson, K Cascino, AA Ordonez, W Zhou, A Vaghasia, ...
Cell reports 34 (11), 108863, 2021
|Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung CancerT-cell Dynamics …|
J Zhang, Z Ji, JX Caushi, M El Asmar, V Anagnostou, TR Cottrell, ...
Clinical Cancer Research 26 (6), 1327-1337, 2020
|Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer|
JE Reuss, V Anagnostou, TR Cottrell, KN Smith, F Verde, M Zahurak, ...
Journal for immunotherapy of cancer 8 (2), 2020
|Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses|
AG Dykema, B Zhang, BA Woldemeskel, CC Garliss, LS Cheung, ...
The Journal of clinical investigation 131 (10), 2021
|Selective Induction of CTL Helper Rather Than Killer Activity by Natural Epitope Variants Promotes Dendritic Cell–Mediated HIV-1 Dissemination|
RB Mailliard, KN Smith, RJ Fecek, G Rappocciolo, EJM Nascimento, ...
The Journal of Immunology 191 (5), 2570-2580, 2013
|Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial|
PM Forde, V Anagnostou, Z Sun, SE Dahlberg, HL Kindler, N Niknafs, ...
Nature medicine 27 (11), 1910-1920, 2021
|Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal TumorsMSS Colorectal Tumor Immune Microenvironment|
NJ Llosa, B Luber, AJ Tam, KN Smith, N Siegel, AH Awan, H Fan, T Oke, ...
Clinical Cancer Research 25 (17), 5250-5259, 2019
|Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers.|
JE Chaft, PM Forde, KN Smith, V Anagnostou, T Cottrell, JM Taube, ...
Journal of Clinical Oncology 35 (15_suppl), 8508-8508, 2017
|Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1|
KN Smith, NJ Llosa, TR Cottrell, N Siegel, H Fan, P Suri, HY Chan, H Guo, ...
Journal for immunotherapy of cancer 7, 1-8, 2019
|NSCLC, early stage neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer|
PM Forde, KN Smith, JE Chaft, M Hellmann, T Merghoub, JD Wolchok, ...
Annals of Oncology 27, vi576, 2016
|Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells|
KN Smith, RB Mailliard, PA Piazza, W Fischer, BT Korber, RJ Fecek, ...
MBio 7 (3), e00473-16, 2016